Chocolate Touch drug-coated angioplasty balloon for treatment of PAD receives FDA approval

1859
chocolate
The Chocolate Touch drug-coated balloon angioplasty balloon

Genesis MedTech Group announced that the US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) catheter, developed by TriReme Medical, for the treatment of patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and the popliteal artery. 

The Chocolate Touch DCB was shown to have statistically superior patency and non-inferior safety at 12 months as compared with Lutonix DCB based on a head-to-head, randomised trial of patients with symptomatic femoropopliteal disease. 

The Chocolate Touch showed statistically superiority in its primary efficacy endpoint of 12-month true DCB success—a measure of the target vessel remaining patent without the need for bail-out stenting. Primary patency by Kaplan-Meier (KM) estimate was 83.3% for the Chocolate Touch and 73.0% for Lutonix DCB at 12 months.

The primary safety endpoint of 12-month freedom from major adverse events (MAEs) was 88.9% for those treated with the Chocolate Touch versus 84.6% for Lutonix DCB.

Additionally, Chocolate Touch results reported the lowest all-cause KM mortality value as compared to reported mortality for FDA-approved DCBs in pivotal studies. Mortality rates for Chocolate Touch using KM estimates at three years were 6.7% for the Chocolate Touch and 11.1% for the Lutonix DCB.   

“I am very excited to see the Chocolate Touch, a next-generation DCB, is now available for patients across the USA. This technology is an important tool in the armamentarium for the treatment of patients with PAD,” stated Mehdi H Shishehbor, interventional cardiologist at University Hospitals Harrington Heart and Vascular Institute (Cleveland, USA) and the Chocolate Touch trial’s co-principal investigator. 

Chocolate Touch is designed to open in small sections using pillow-like structures coated with a therapeutic agent with the goal of providing patients suffering from PAD with an alternative treatment to traditional DCB angioplasty. 

“This next-generation paclitaxel DCB is based on the chocolate mechanism of pillow-and-groove formation resulting in an increased balloon surface facilitating effective drug release to the vessel wall and potentially reducing the need for permanent implants.  The recently completed randomised, controlled study demonstrated excellent primary results, with statistical superior effectiveness as compared to the control DCB. The Chocolate Touch is a DCB category of its own,” commented co-principal investigator Thomas Zeller of Universitaets-Herzzentrum (Bad Krozingen, Germany).


LEAVE A REPLY

Please enter your comment!
Please enter your name here